

# ARYZTA AG

## News Release

---

**Zurich/Switzerland, 24 September 2012 – ARYZTA AG announces financial results for the financial year ended 31 July 2012**

---

### Key Performance Highlights

#### Food Group

- Revenue increase of 11.3% to €2.87bn.
  - Food Europe increased by 7.5%.
  - Food North America increased by 13.2%.
  - Food Rest of World increased by 23.0%.
- EBITA increase of 16.3% to €374.8m.
  - Food Europe increased by 13.7%.
  - Food North America increased by 18.6%.
  - Food Rest of World increased by 18.0%.
- Net debt: EBITDA ratio of 2.05x.
- The weighted average maturity of the Food Group gross term debt is circa 5.94 years.
- Weighted average interest cost of Food Group debt financing facilities of circa 4.68%.

#### Origin

- Revenue increase of 3.1% to €1.34bn.
- Origin Enterprises underlying fully diluted EPS growth of 4.2% to 45.16 cent.
- Performed to expectation.

#### Group

- Group revenue increased by 8.5% to €4.21bn.
- Group EBITA increased by 12.9% to €444.1m.
- Group EBITA margin increased by 50bps to 10.6%.
- Underlying fully diluted EPS increased by 8.8% to 337.5 cent.

*Commenting on the results, ARYZTA AG Chief Executive Officer Owen Killian said:*

“ARYZTA’s performance in FY 2012 was satisfactory given the challenging macro environment. Weak consumer spending affected our customers and the impact of government austerity measures was particularly noticeable in Europe. The business performance reflects the benefits of good progress on implementing internal transformation measures designed to better support our customers. This will continue throughout FY 2013.

Resurgent food inflation adds additional challenges for ARYZTA and its customers. We remain focused on working closely with our customers to manage inflationary pressures in order to maintain affordability without compromising quality or service.

## ARYZTA AG

# News Release

---

We have no great expectation of any recovery in consumer behaviour during FY 2013 to support revenue growth and therefore expect underlying fully diluted EPS growth to broadly mirror FY 2012 with an increase of 5% –10%.”

The ARYZTA Full Year Results for the year ended 31 July 2012 are available for download from the ARYZTA website and at the following link:  
<http://www.aryzta.com/2012-FullYear-Results>

---

### About ARYZTA

ARYZTA AG ('ARYZTA') is a global food business with a leadership position in speciality bakery. ARYZTA is based in Zurich, Switzerland, with operations in North America, South America, Europe, Asia, Australia and New Zealand. ARYZTA has a primary listing on the SIX Swiss Exchange and a secondary listing on the ISE Irish Exchange (SIX: ARYN, ISE: YZA).

ARYZTA is the majority shareholder (68.8%) in Origin Enterprises plc, which has a listing on the AIM in London and the ESM in Dublin (AIM: OGN, ESM: OIZ).

---

### Enquiries:

Paul Meade  
Communications Officer  
ARYZTA AG  
Tel: +41 (0) 44 583 42 00  
[info@aryzta.com](mailto:info@aryzta.com)

---

### Analyst conference call

An analyst call will take place today at 09:00 CET (08:00 GMT).

Dial in numbers are: Switzerland: 0565 800 007, Ireland 01 506 0153, UK 0844 493 3800, USA 1 631 510 7498, International +44 (0) 1452 555 566. Please provide the following code: 25679718 to access the call.

Printable pdf version of slides will be available to download from the ARYZTA website [www.aryzta.com](http://www.aryzta.com) 15 minutes before the call.

A conference call webcast replay will be available from the ARYZTA website [www.aryzta.com](http://www.aryzta.com)

# ARYZTA AG

# News Release

---

## **Forward looking statement**

This document contains forward looking statements which reflect management's current views and estimates. The forward looking statements involve certain risks and uncertainties that could cause actual results to differ materially from those contained in the forward looking statements. Potential risks and uncertainties include such factors as general economic conditions, foreign exchange fluctuations, competitive product and pricing pressures and regulatory developments.